The Dr. Makis Cancer Protocol Guide

In recent years, public interest has grown around alternative and repurposed drugs being discussed in the context of cancer care. Among these discussions is what is often referred to as the “Dr. Makis Cancer Protocol,” a concept associated online with Dr. William Makis and centered around the exploratory use of drugs such as ivermectin and fenbendazole. These substances, originally developed and approved for anti-parasitic use in humans and animals respectively, have been the subject of informal reports, anecdotal claims, and online discourse suggesting possible roles in broader biological processes, including cancer. However, these ideas remain outside mainstream oncology practice and are not recognized as established cancer treatments by major medical authorities. This guide examines the protocol concept from an informational and critical perspective, aiming to clarify what is known, what is hypothesized, and what remains unproven. It is important to understand that cancer is a complex group of diseases involving uncontrolled cell growth driven by multiple genetic and environmental factors. Standard treatments such as surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies are supported by extensive clinical research and regulatory approval processes. In contrast, the use of ivermectin and fenbendazole in cancer-related contexts is based largely on laboratory studies, theoretical mechanisms, and anecdotal reports rather than large-scale, peer-reviewed clinical trials in humans. Ivermectin is an anti-parasitic medication widely used to treat conditions such as river blindness and scabies. In laboratory settings, some studies have explored its effects on cellular pathways, including inflammation and cell signaling. These findings have led to hypotheses about potential anti-cancer properties, but such results have not been conclusively demonstrated in clinical oncology settings. Similarly, fenbendazole is a veterinary anti-parasitic drug that has attracted attention through online narratives suggesting anti-tumor effects. While some preclinical research and anecdotal accounts have circulated, there is currently insufficient high-quality evidence to support its safety or effectiveness as a cancer treatment in humans. The “Makis Protocol” is often described in online communities as a combination or sequential use of these compounds, sometimes alongside vitamins or other supportive substances. However, there is no universally accepted medical protocol under this name within oncology literature, and its components, dosing strategies, and clinical outcomes are not standardized or validated through controlled trials. As such, it is best understood as a collection of informal ideas rather than an evidence-based treatment framework. Given the sensitivity of cancer care, evaluating such claims requires careful scientific scrutiny. Patients facing serious illness are often vulnerable to misinformation or unverified treatment promises, making it essential to distinguish between experimental hypotheses and clinically validated therapies. Regulatory agencies and oncology organizations consistently emphasize the importance of evidence-based medicine, particularly when dealing with life-threatening conditions. This introduction sets the foundation for a deeper exploration of the individuals, substances, theories, and controversies surrounding the topic. It also highlights the importance of critical thinking, medical consultation, and reliance on peer-reviewed evidence when considering any emerging or alternative approaches to cancer care.